New immunotherapy for cervical cancer that stopped responding to prior treatment
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug (QL1706) for cervical cancer that has stopped responding to earlier PD-1 therapies. The goal is to see if this drug can help shrink tumors or slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have cervical cancer that has spread to other parts of the body or come back after treatment.
- You must have already tried a PD-1 inhibitor (like pembrolizumab or nivolumab) and it stopped working.
- You must be physically active enough to do light work, but not heavy physical work (ECOG 0 or 1).
- You must have a tumor that can be measured on a scan.
- You must have adequate kidney, liver, and blood cell function (this will be checked with blood tests).
- You must not have certain heart, immune, or other serious health conditions that could interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
This trial tests giving a combination of an immunotherapy drug (QL1706) and two chemotherapy drugs (cisplatin and paclitaxel) before surgery for cervical cancer. The goal is to shrink the tumor to make surgery more effective and improve outcomes.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This trial tests a new drug called QL706 combined with chemotherapy, with or without another drug called bevacizumab, for people with cervical cancer that has returned or spread and no longer responds to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.